345 results on '"Woodman, Richard C."'
Search Results
52. Assessment of Clinical Safety and Estimate of Survival in Iraqi Patients with Chronic Myeloid Leukemia Switched From Glivec (β-Crystalline Form of Imatinib Mesylate) to an α-Crystalline Copy of Imatinib Mesylate
53. Nilotinib Versus High-Dose Imatinib in Early Chronic Phase CML Patients Who Have Suboptimal Molecular Responses to Standard-Dose Imatinib: Updated Data From RE-Nice Study
54. Nilotinib population pharmacokinetics and exposure-response analysis in patients with imatinib-resistant or -intolerant chronic myeloid leukemia
55. Efficacy of Nilotinib Versus High-Dose Imatinib in Early Chronic Phase CML Patients Who Have Suboptimal Molecular Responses to Standard-Dose Imatinib (RE-NICE Multicenter Study)
56. Retrospective Cohort Analysis of Peripheral Arterial Occlusive Disease (PAOD) Events in Patients (pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP)
57. A Review of Mutation Analysis In the TOPS Trial of Standard Dose Versus High Dose IM In CML Suggests That Refinements to the ELN Recommendations for Mutation Screening May Be Appropriate
58. Hospitalizations of Patients with Newly Diagnosed CML-CP Treated with Nilotinib or Imatinib: Results From a Randomized Phase III Trial
59. Nilotinib Exposure-Response Analysis In Patients with Imatinib-Resistant or -Intolerant Chronic Myeloid Leukemia (CML)
60. Molecular Predictors for the Response to Nilotinib Treatment After Acquired Imatinib Failure In Ph+ Chronic Myeloid Leukemia
61. Comparative In Vitro Cellular Data Alone Are Insufficient to Predict Clinical Responses and Guide the Choice of BCR-ABL Inhibitor for Treating Imatinib-Resistant Chronic Myeloid Leukemia
62. Molecular Response at 3 Months On Nilotinib Therapy Predicts Response and Long-Term Outcomes in Patients with Imatinib-Resistant or -Intolerant Chronic Myeloid Leukemia in Chronic Phase (CML-CP).
63. Comparative in Vitro Cellular Data Alone Is Insufficient to Predict Clinical Responses and Guide Choice of BCR-ABL Inhibitor to Treat Imatinib-Resistant Chronic Myeloid Leukemia.
64. MDR1 Expression and Pre-Treatment Tumor Load Predict Molecular Response in CML Patients On Nilotinib Therapy After Imatinib Failure.
65. Prognostic Factors for Progression-Free Survival in Patients with Imatinib-Resistant or -Intolerant Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated with Nilotinib Based On 24 Month Data.
66. Response and Outcomes to Nilotinib at 24 Months in Imatinib-Resistant Chronic Myeloid Leukemia Patients in Chronic Phase (CML-CP) and Accelerated Phase (CML-AP) with and without BCR-ABL Mutations.
67. Nilotinib Treatment in Pediatric Patients (pts) with Philadelphia Chromosome- Positive (Ph+) Leukemia Refractory to Prior Tyrosine Kinase Inhibitor (TKI) Therapy: Results from Nilotinib Compassionate Use Program
68. Occurrence of Pleural/Pericardial Effusions in Ph+ CML Patients Failing Prior Tyrosine Kinase Inhibitors (TKI) Before Starting Nilotinib – Retrospective Analysis upon Entry into the Nilotinib Compassionate Use Program
69. The Cost of Managing Pleural Effusion Associated with Dasatinib in CML Patients Post Imatinib Failure.
70. Short-Term Cost Per Responder among New Tyrosine Kinase Inhibitors for Imatinib-Resistant CML in Chronic Phase (CML-CP) — Canada and Germany Perspectives.
71. Evaluation of the Impact of Myelosuppression on Treatment Response and Health-Related Quality of Life (HRQoL) in Patients with Chronic Myeloid Leukemia (CML).
72. Anemia and cognitive performance in hospitalized older patients: results from the GIFA study
73. Hemoglobin and All-Cause Mortality: Results from the Baltimore Longitudinal Study of Aging (BLSA).
74. Maintenance Dosing with Epoetin alfa Every Two Weeks (Q2W) in Anemic Patients with Cancer Receiving Chemotherapy Every One or Four Weeks: Final Results.
75. Anemia in the Elderly and the Risk of Injurious Falls.
76. The Impact of Hemoglobin on Total Mortality in Elderly Asian-American Men: The Honolulu Heart Program.
77. Impact of Anemia on the Medical Cost of Injurious Falls in the Elderly.
78. Iron Deficiency Is Common in Anemic Elderly Patients: Results with sTfr Index.
79. Maintenance Dosing with Epoetin alfa Every Three Weeks (Q3W) in Anemic Patients with Cancer Receiving Chemotherapy Every Three Weeks: Final Results.
80. Randomized, Open-Label Study of Epoetin alfa 40,000 U Once Weekly Versus 80,000 U Every Two Weeks in Anemic Patients with Cancer Receiving Chemotherapy.
81. Proinflammatory state and circulating erythropoietin in persons with and without anemia
82. Hemoglobin Levels and Bone Density in Older Persons: Results from the Inchianti Study.
83. Anemia and Cardiovascular Disease (CVD) Synergistically Interact To Increase the Risk of Frailty in Community-Dwelling Older Women.
84. Anemia in Two Groups of Elderly (65–79 and >/=80) Patients with Chronic Kidney Disease (CKD).
85. Anemia and Associated Comorbidities among the Elderly.
86. Treatment of CKD Anemia in Octogenarians: A Comparison of Epoetin Alfa (EPO) in Elderly (65–79; >/=80) and Non-Elderly (<65) Patients.
87. Circulating Erythropoietin (EPO) and Pro-Inflammatory Markers in Elderly (>/=65) Persons with and without Anemia.
88. Primary Amyloidosis Presenting as Small Bowel Encapsulation
89. Sustained Cyclosporine-Induced Erythropoietic Response in Identical Male Twins With Diamond-Blackfan Anemia
90. P38 MAPK: critical molecule in thrombin-induced NF-κB-dependent leukocyte recruitment
91. Successful Treatment of Posttransplant Lymphoproliferative Disorder in a Renal Transplant Patient by Autologous Peripheral Blood Stem Cell Transplantation
92. Selective recruitment of neutrophils and lymphocytes by thrombin: a role for NF-κB
93. Trisomy 21 and isodicentric chromosome 21 in Kostmann syndrome following treatment with G-CSF
94. Crohn-like Enteritis Presenting as Hypoglycemia in a Patient With Glycogen Storage Disease Type 1b, Treated With Granulocyte Colony-stimulating Factor and Splenectomy
95. Patient and Provider Readiness for Personalized Medicine.
96. Deep venous thrombosis in hemophilia A
97. A High Affinity Binding Site for [3H]-Dofetilide on Human Leukocytes
98. Antithrombin III Prevents and Rapidly Reverses Leukocyte Recruitment in Ischemia/Reperfusion
99. A novel β 1 ‐dependent adhesion pathway on neutrophils: a mechanism invoked by dihydrocytochalasin B or endothelial transmigration
100. Detection of Nitric Oxide by Bioassay
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.